Table 4.
Pre-treatment and post-treatment weighted means in anthropometric variables in TZD and placebo treated patients with NASH
| Parameter | Arm | Weighted mean pre-treatment | Weighted mean post-treatment | P-value |
|---|---|---|---|---|
| Wt (kg) | Control | 92.48 (n = 166) | 91.65 (n = 157) | 0.3 |
| TZD | 90.18 (n = 251) | 94.17 (n = 236) | <0.0001 | |
| BMI (kg/m2) | Control | 31.80 (n = 190) | 31.16 (n = 181) | <0.01 |
| TZD | 31.12 (n = 287) | 31.85 (n = 272) | <0.0001 | |
| Total body fat (%) | Control | 37.64 (n = 129) | 37.09 (n = 120) | 0.05 |
| TZD | 34.60 (n = 209) | 36.40 (n = 199) | <0.0001 | |
| Liver fat (%) | Control | 17.20 (n = 21) | 17.20 (n = 21) | 0.5 |
| TZD | 21.28 (n = 44) | 10.08 (n = 44) | <0.0001 | |
| Fasting FFA (μEq/L) | Control | 720.00 (n = 21) | 798.00 (n = 21) | 0.07 |
| TZD | 735.60 (n = 44) | 606.99 (n = 44) | <0.003 | |
| Waist circumf (cm) | Control | 105.99 (n = 108) | 103.81 (n = 99) | 0.06 |
| TZD | 101.00 (n = 183) | 100.17 (n = 173) | 0.05 | |
| Waist-hip ratio | Control | 0.97 (n = 37) | 0.96 (n = 37) | 0.06 |
| TZD | 0.96 (n = 115) | 0.92 (n = 115) | <0.002 |
BMI, body-mass-index; FFA, fasting free fatty acids; fasting waist circumf, waist circumference; NASH, non-alcoholic steatohepatitis; TZD, thiazolidinediones; Wt, weight.
Significant p-values are in bold.